Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ:ACLX)

64.10 -0.03 (-0.05%)
Streaming Delayed Price Updated: 3:58 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Navigating 7 Analyst Ratings For Arcellx ↗
 
Via Benzinga
News headline image
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
From Arcellx, Inc.
Via Business Wire
News headline image
Cracking The Code: Understanding Analyst Reviews For Arcellx ↗
 
Via Benzinga
News headline image
4 Analysts Assess Arcellx: What You Need To Know ↗
 
Via Benzinga
News headline image
Assessing Arcellx: Insights From 7 Financial Analysts ↗
 
Via Benzinga
News headline image
Decoding 8 Analyst Evaluations For Arcellx ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings For Arcellx ↗
 
Via Benzinga
News headline image
Expert Ratings For Arcellx ↗
 
Via Benzinga
News headline image
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q2 2024 ↗
ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Arcellx Provides Second Quarter 2024 Financial Results and Business Updates
From Arcellx, Inc.
Via Business Wire
News headline image
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals ↗
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals. 
Via InvestorPlace
News headline image
Arcellx Stock Earns Relative Strength Rating Upgrade ↗
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83. 
Via Investor's Business Daily
News headline image
7 Biotech Stocks to Put on Your Breakthrough Radar ↗
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
News headline image
Analyst Expectations For Arcellx's Future ↗
 
Via Benzinga
News headline image
Peering Into Arcellx's Recent Short Interest ↗
 
Via Benzinga
News headline image
Arcellx Analysts Boost Their Forecasts After Q4 Results ↗
Arcellx, Inc. (NASDAQ: ACLX) posted financial results for its fourth quarter on Wednesday. 
Via Benzinga
News headline image
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024 ↗
ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Arcellx, Inc.
Via Business Wire
News headline image
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Arcellx Provides First Quarter 2024 Financial Results
From Arcellx, Inc.
Via Business Wire
News headline image
Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine ↗
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot. 
Via InvestorPlace
News headline image
Arcellx to Participate in Two Upcoming Investor Conferences
From Arcellx, Inc.
Via Business Wire
News headline image
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Arcellx, Inc.
Via Business Wire
News headline image
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
From Arcellx, Inc.
Via Business Wire
News headline image
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley ↗
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales. 
Via Benzinga
News headline image
The 3 Biotech Stocks That Could Make Your February Unforgettable ↗
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. 
Via InvestorPlace
News headline image
Decoding Bearish Analog And The Warning Signs You Can't Ignore ↗
A look at the bearish analog structure that the S&P 500 could be unfolding and the 3 warning signs you can't ignore. 
Via Talk Markets
Topics Stocks
News headline image
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market ↗
Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry. 
Via InvestorPlace
News headline image
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 ↗
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.